

ABSTRACT OF THE DISCLOSURE

The invention discloses the *Neisseria meningitidis* NMA SP polypeptide, polypeptides derived therefrom (NMA SP-derived polypeptides), nucleotide sequences encoding said polypeptides, and antibodies that specifically bind the NMA SP polypeptide and/or NMA SP-derived polypeptides. Also disclosed are prophylactic or therapeutic compositions, including immunogenic compositions, e.g., vaccines, comprising NMA SP polypeptide and/or a NMA SP-derived polypeptide. The invention additionally discloses methods of inducing a immune response to *Neisseria meningitidis* and *Neisseria meningitidis* NMA SP polypeptide and an NMA SP-derived polypeptide in animals.